Ruheena Yasmeen, Humera Hafsa Jabeen, Raafia Aseena, Kaunain Taneem, Umer Syed
Ruheena Yasmeen1, Humera Hafsa Jabeen2, Raafia Aseena3, Kaunain Taneem4, Umer Syed5
1Assistant Professor, Nizam Institute of Pharmacy, Deshmukhi.
2,3,4,5Pharm.D Student, Nizam Institute of Pharmacy, Deshmukhi
Volume - 14,
Issue - 10,
Year - 2021
Introduction: The clinical spectrum of NAFLD is wide extending and ranges from NAFL to NASH, advanced fibrosis, cirrhosis, HCC. It has emerged as the most prevalent chronic liver disease worldwide in adults and children's. NAFLD is commonly linked with MS such as obesity, DM, H0TN, hypercholesterolemia. Methods: This is an observational study conducted to determine risk factor, severity and complication associated with NAFLD. Data was collected from outpatient and inpatients of gastroenterology department and also through patient or care taker interview. Result: A total of 112 cases of liver disease were observed among them 61 cases were found with NAFLD. Majority of cases were examined with Grade I fatty liver. Males were more prone to develop NAFLD and the most highest prevalence was found in the age group 51-70yrs. DM is the main RF and PHTN is the common complication observed. Beta blocker, ARB, statins, are frequently observed prescribed drugs to manage risk factors and complication. Hepatoprotective drugs like ursodeoxycholic acid, SAMe are given. Conclusion: The study concluded that the prevalence of Grade I fatty liver was high followed by CLD. Further, patients with NAFLD were predominantly middle aged men, most of whom were overweight and obese. Prevalence of NAFLD appears to be substantially higher than that predicted on basis of elevated ALT levels. Male sex, BMI, abnormal transaminase level, and MS were independently associated with ultrasonographic severe fatty change. Early detection, as well as steps to prevent the condition through lifestyle modification may halt the progression of a benign disease to advanced illness. Sedentary behavior or physical inactivity is a developing issue quietly putting individuals at elevated risk.
Cite this article:
Ruheena Yasmeen, Humera Hafsa Jabeen, Raafia Aseena, Kaunain Taneem, Umer Syed. An Observational Study to Determine Severity and Complications Associated with Non-Alcoholic Fatty Liver Disease with Special Emphasis on Riskfactors. Research Journal of Pharmacy and Technology 2021; 14(10):5498-2. doi: 10.52711/0974-360X.2021.00959
Ruheena Yasmeen, Humera Hafsa Jabeen, Raafia Aseena, Kaunain Taneem, Umer Syed. An Observational Study to Determine Severity and Complications Associated with Non-Alcoholic Fatty Liver Disease with Special Emphasis on Riskfactors. Research Journal of Pharmacy and Technology 2021; 14(10):5498-2. doi: 10.52711/0974-360X.2021.00959 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-10-77
1. Naga Chalasani, Zobair Younossi et.al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Clinical liver disease. A Multimedia Review Journal. 2018 Jan; 67(1):328-357
2. JinshengYu, SharonMarsh, et. al. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterology Research and Practise. January 2016, volume 2016
3. Fan JG, et.al. New trends on obesity and NAFLD in Asia. J Hepatol. 2017 Oct 67(4):862-873.
4. Charles Daniel. Overview of ALT and AST Liver Enzymes. Medically reviewed by a board-certified physician; Updated November 08, 2018.
5. Gastroenterology-family practice note book llc [US] https://fpnotebook.com/GI/Exam/BrdScr.htm.
6. Arun J. Sanyal et.al. Portal Hypertension and Its Complications. Gastroenterology.2008 ;134:1715-1728.
7. J K Dyson et al. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. BMJ Journal.2015; Volume 91, issue 1072.
8. Sanjay Kalra1, Manoj Vithalani2 , et.al. Study of Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Patients in India (SPRINT). The Journal of Association of Physicians of India. 2013 Jul;61(7):448-53.
9. Girish K Pati and Shivaram P Singh. Nonalcoholic Fatty Liver Disease in South Asia. Euroasian J Hepatogastroenterol. 2016 Jul-Dec; 6(2): 154–162.
10. Alajos Par. Epidemiology of NAFLD. Bentham Science Publishers. 2018 Pp. 3-20(18)
11. Rachel M. Williamson, Jackie F. Price et.al. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011 May; 34(5): 1139–1144.
12. Singh SP, Kar SK, et.al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India.Tropical Gastroenterology :Official Journal of Digestive Diseases Foundation. 2013 Jul-Sep;34(3):144-152.
13. Paul Angulo, Elisabetta Bugianesi et.al. Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2013;145:782–789. 14. Vera S. G. Ferreira, Ricardo B. Pernambuco et.al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metab. June 2010 vol.54 no.4.
14. McPherson S, Stewart SF et.al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010 Sep;59(9):1265-9.
15. Hana’a Mahmoud Al-Dayyata, et.al. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12 (2018) 569–575 17. Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol (2014) 20(25):8102–9.
16. Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol (2014) 20(25):8102–9.
17. Laura Marino and François R Jornayvaz. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol. 2015 Oct 21;21(39):11053-1107619. Flavia D. Mendes, Ayako Suzuki et.al. Prevalence and Indicators of Portal Hypertension in Patients with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9): 1028-1033.
18. Flavia D. Mendes, Ayako Suzuki et.al. Prevalence and Indicators of Portal Hypertension in Patients with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9): 1028-1